• Explore /
  • Poster
  • / Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.

Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.

Abstract Poster

Authors

Daniel Spratt

Daniel Eidelberg Spratt

University Hospitals Seidman Cancer Center, Cleveland, OH

Daniel Eidelberg Spratt , Huei-Chung Huang , Jeff M. Michalski , Elai Davicioni , Alejandro Berlin , Jeff Simko , Jason A. Efstathiou , Phuoc T. Tran , Darby Thompson , Matthew Parliament , Ian S. Dayes , Rohann Correa , John M. Robertson , Elizabeth Gore , Desiree E. Doncals , Eric Vigneault , Luis Souhami , Theodore Karrison , Felix Y Feng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT00033631

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 269)

DOI

10.1200/JCO.2022.40.6_suppl.269

Abstract #

269

Poster Bd #

M1

Abstract Disclosures

Similar Posters

First Author: Avery Braun

First Author: Alan Dal Pra

Poster

2021 Genitourinary Cancers Symposium

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up.

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up.

First Author: Michael Austin Brooks

First Author: Eric Margolis